A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
Phase of Trial: Phase II
Latest Information Update: 05 Mar 2018
At a glance
- Drugs INCB 54828 (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Acronyms FIGHT-201
- Sponsors Incyte Corporation
- 14 Dec 2017 Planned number of patients changed from 100 to 140.
- 14 Dec 2017 Planned End Date changed from 1 Sep 2018 to 1 Jan 2019.
- 14 Dec 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.